The case, published in Frontiers in Medicine by a team led by Jiankai Long, Jingnan Xue, and Kai Zhou of the People’s Hospital of Anshun City, with collaborators from Peking Union Medical College Hospital, describes an intrahepatic intraductal papillary neoplasm of the bile duct, or IPNB, with low-grade dysplasia of the pancreatobiliary type. IPNB is an uncommon biliary epithelial neoplasm characterized by papillary or villous proliferation within the bile duct lumen, often accompanied by bile duct dilatation and mucin hypersecretion. It is increasingly recognized as an important precursor lesion of cholangiocarcinoma, an aggressive cancer of the bile ducts. The histological grade, invasive status, and subtype of IPNB are closely associated with prognosis and management strategies, which makes accurate preoperative recognition a matter of genuine clinical urgency.

The diagnostic challenge in this case was not simply the rarity of the tumor itself. It was the fact that everything about the patient’s presentation—recurrent biliary symptoms, multiple intrahepatic stones, and evidence of ductal obstruction—could be explained by uncomplicated hepatolithiasis with secondary obstruction. In such settings, the main clinical risk is misinterpreting a true intraductal neoplasm as stone-related biliary disease. The authors emphasize that focal or unilateral bile duct dilatation, localized obstructive change, intraductal soft-tissue components, or abundant mucin may indicate IPNB rather than hepatolithiasis alone, and that recognizing this pitfall is essential for timely intervention.

On admission, physical examination revealed no remarkable findings. Laboratory investigations, including complete blood count, liver and renal function tests, and coagulation profile, were within normal limits. The only abnormality was a mildly elevated serum carbohydrate antigen 19-9, or CA19-9, level of 39.8 U/mL—a tumor marker that can be elevated in biliary malignancies but is nonspecific and can also rise in benign cholestatic conditions. Routine blood work offered no clear signal that a neoplasm was lurking within the left intrahepatic biliary system.

The real clues emerged from cross-sectional imaging. Contrast-enhanced computed tomography demonstrated a focal intraductal adenomatous lesion in the left intrahepatic biliary system with adjacent cystic or aneurysmal dilatation of the affected bile duct, producing the appearance of localized high biliary obstruction. The lesion was centered near the left hepatic hilar region and was associated with unilateral left intrahepatic biliary dilatation. Magnetic resonance imaging and magnetic resonance cholangiopancreatography, or MRCP, further confirmed marked unilateral dilatation of the left intrahepatic bile ducts with focal hilar-level obstructive change and an associated intraductal abnormality. The predominantly unilateral distribution of ductal dilatation and the localized obstructive appearance were atypical for simple hepatolithiasis alone and raised concern for an underlying intraductal biliary neoplasm.

This imaging pattern is technically significant because hepatolithiasis typically produces diffuse, bilateral, or multifocal ductal changes proportional to the stone burden. When dilatation is focal or unilateral and appears disproportionate to the stones, the differential diagnosis should expand beyond stone disease. In this case, the preoperative differential diagnosis included hepatolithiasis with cholangitis, intrahepatic cholangiocarcinoma, mucinous biliary neoplasm, and IPNB. The radiologic-pathologic correlation proved particularly informative: the focal intraductal lesion and adjacent dilated bile duct seen on CT corresponded to the gross finding of papillary adenomatous tissue within a markedly dilated bile duct containing gelatinous material, and to the microscopic finding of papillary epithelial proliferation on histopathology. This correlation helped explain why the lesion was not merely a consequence of stone disease but represented a true intraductal neoplasm.

Given that the lesion appeared localized to the left intrahepatic biliary system and that the patient had recurrent obstructive symptoms, the surgical team selected definitive treatment after comprehensive preoperative evaluation. The patient underwent open left hepatectomy under general anesthesia. Intermittent inflow occlusion using the Pringle maneuver—a technique that temporarily clamps the hepatoduodenal ligament to reduce blood loss during liver resection—was applied, with a total clamping time of 30 minutes. Intraoperative blood loss was approximately 20 mL, and the patient remained hemodynamically stable throughout the procedure. Gross examination of the resected specimen demonstrated a markedly dilated bile duct containing intraductal papillary adenomatous tissue and gelatinous mucinous material. For lesions confined to one intrahepatic biliary system, hepatectomy can provide both definitive diagnosis and curative treatment in a single operation.

Histopathological examination confirmed intrahepatic IPNB with low-grade dysplasia of the pancreatobiliary type. No invasive carcinoma was identified, and all resection margins were negative—findings that carry substantial prognostic weight. Immunohistochemical staining showed that the neoplastic biliary epithelium was positive for CK19, CK7, MUC1, MUC5AC, and MUC6, but negative for MUC2. This mucin profile is technically meaningful because it supports pancreatobiliary differentiation and strengthens subtype classification beyond morphology alone, enabling more meaningful comparison with previously reported cases. The postoperative course was uneventful, and the patient was discharged on postoperative day 10 without documented complications such as bile leakage, hemorrhage, or severe infection.

During two years of outpatient follow-up, the patient remained clinically stable with no evidence of recurrence or major postoperative complications. Her abdominal symptoms resolved after surgery, and her quality of life improved. The latest CT demonstrated postoperative changes after left hepatectomy, possible intrahepatic bile duct calculi or calcifications, mild intrahepatic and extrahepatic bile duct dilatation, and a right renal cyst, but no definite recurrent lesion was reported. After surgery, the patient reported that her pain had resolved and that follow-up examinations were reassuring, expressing satisfaction with the treatment outcome and feeling more secure in her daily life.

The authors caution that even low-grade, completely resected IPNB requires long-term surveillance, because biliary neoplasms may recur or present as multifocal disease. Patients with IPNB should undergo periodic clinical review and hepatobiliary imaging after surgery, especially during the first two postoperative years. The report has limitations: several detailed preoperative radiologic parameters, including reproducible lesion measurements, formal enhancement characteristics, and complete archived MRCP descriptors, were unavailable, and as a single-case report the generalizability of the findings is inherently limited. The two-year follow-up duration may also be insufficient to exclude late recurrence or multifocal disease. Nevertheless, the central message stands: in patients with hepatolithiasis and recurrent biliary symptoms, unilateral or focal intrahepatic duct dilatation, localized obstructive change, and intraductal abnormalities should prompt consideration of IPNB rather than uncomplicated stone disease alone. Early recognition, timely surgical resection for localized disease, and complete pathological evaluation are essential for accurate diagnosis, risk stratification, and follow-up planning—and this case shows how a tumor hiding behind stones can be caught before it becomes cancer.

Subject of Research: Medicine

Article Title: Intrahepatic intraductal papillary neoplasm of the bile duct with low-grade dysplasia presenting as high biliary obstruction and hepatolithiasis: a case report

Article References: Long, J., Xue, J., Xie, N., Zhang, L., & Zhou, K. (2026). Intrahepatic intraductal papillary neoplasm of the bile duct with low-grade dysplasia presenting as high biliary obstruction and hepatolithiasis: a case report. Frontiers in Medicine, 13, Article 1916026. https://doi.org/10.3389/fmed.2026.1916026

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1916026

Keywords: IPNB, bile duct, hepatolithiasis, cholangiocarcinoma, case report, hepatectomy, biliary obstruction, precancerous, mucin, diagnostic pitfall, Intrahepatic, intraductal

The central discovery concerns fucosylation, the attachment of fucose sugars to mucin 2, or MUC2, the gel-forming glycoprotein that constitutes the bulk of the colonic mucus layer. Fucose residues added to MUC2 are not cosmetic. They alter the mucus matrix in ways that support its integrity and its interactions with the microbial community. In colitis, this fucosylation is lost, and the mucus barrier weakens, leaving the epithelial surface exposed. The new study shows that the flagellin of L. 3–1-57, the protein that forms the propeller-like appendage of the bacterium, can reverse this deficit through a defined immunological cascade.

The clinical foundation of the work rests on two cohorts of human participants. Compared with healthy controls and with patients whose ulcerative colitis was in remission, patients with active disease showed reduced abundance of L. 3–1-57 in their gut microbiota. The depletion was not random. The lower the abundance of the bacterium, the more severe the disease, an inverse correlation that held across the study population. This pattern suggests that L. 3–1-57 is not merely a passive bystander in colitis but a component of the microbial community whose presence tracks with mucosal health.

To test whether the relationship is causal, the team turned to mouse models of chemically induced colitis. Oral administration of live L. 3–1-57 attenuated intestinal inflammation and mucus barrier dysfunction. Purified flagellin from the bacterium, delivered without the living organism, achieved the same protection. The contrast with a well-known gut pathobiont was stark: flagellin from Escherichia coli exacerbated disease rather than relieving it. This strain-specific divergence is one of the most technically significant aspects of the study, because flagellins from different bacteria are structurally similar yet immunologically distinct, and the field has lacked a clear account of which commensal flagellins promote homeostasis rather than inflammation.

The mechanistic chain begins at Toll-like receptor 5, or TLR5, the innate immune receptor that recognizes bacterial flagellin. Using binding assays, the researchers demonstrated that L. 3–1-57 flagellin binds TLR5 with high affinity. Upon this engagement, dendritic cells, the antigen-presenting sentinels of the mucosal immune system, are activated to produce interleukin-23. Interleukin-23 in turn expands the population of group 3 innate lymphoid cells, or ILC3s, that produce interleukin-22. Interleukin-22 is a cytokine with well-documented effects on epithelial cells, and in this context it drives the expression of fucosyltransferase 2, the enzyme that catalyzes the α-1,2-linked fucosylation of MUC2. The restored fucosylation rebuilds the mucus matrix and closes the protective loop.

The team then dismantled the pathway piece by piece to confirm that each element is indispensable. Genetic ablation of Tlr5 in mice abolished the protective effect of the flagellin. Pharmacological inhibition of α-1,2-fucosylation eliminated the benefit even when the immune cascade was intact. Neutralization of interleukin-22 likewise erased the protection. These loss-of-function experiments establish that the TLR5–IL-23–IL-22 axis and the fucosylation it drives are not merely correlated with recovery but are required for it, a standard of mechanistic proof that many microbiome studies do not reach.

A further technical point addresses a common concern about flagellin-based therapies. Analysis of the gut microbiota by 16S rRNA amplicon sequencing showed that orally administered L. 3–1-57 flagellin did not induce broad restructuring of the microbial community. The protection, in other words, is not mediated by wholesale alteration of the microbiome but by a targeted immune and glycosylation pathway. Detection of His-tagged flagellin in colonic mucus confirmed that the protein reaches its site of action after oral delivery, and flow cytometric analysis documented the activation of dendritic cells in the colonic lamina propria and mesenteric lymph nodes.

The translational implications are threefold. First, the authors nominate L. 3–1-57 as a candidate next-generation probiotic, a living organism whose administration could restore a depleted protective community member. Second, the flagellin itself is proposed as a postbiotic therapy, a purified microbial product that delivers the benefit without the need for live bacteria, an approach that may offer more predictable dosing and safety. Third, the fecal depletion of L. 3–1-57 is suggested as a noninvasive auxiliary diagnostic biomarker, a measurable microbial signal that could complement clinical assessment of disease activity.

The study also contributes to a broader reevaluation of flagellin, a molecule long viewed with suspicion because of its role in inflammatory signaling. The new work demonstrates that flagellin is not a monolithic inflammatory trigger but a family of strain-specific immunomodulators whose effects depend on the producing organism. Flagellins from commensal bacteria are among the most potent modulators of intestinal immunity, yet their homeostatic functions have remained poorly defined. By identifying a commensal flagellin that promotes mucosal repair through a defined receptor-to-glycosylation pathway, the study provides a framework for distinguishing protective from harmful flagellins and for exploiting the protective ones therapeutically.

The work was supported by the National Natural Science Foundation of China and related funding programs, and was approved by the Ethics Committee of Tianjin Medical University General Hospital and the Tianjin Medical University Animal Care and Use Committee. The article is open access under a Creative Commons license, and the authors declare no competing interests. As with all preclinical microbiome research, the findings in mouse models and human associations will require further validation before clinical application, but the study establishes a complete mechanistic account of how a single commensal bacterium, acting through its flagellin and a defined immune axis, can rebuild the chemical architecture of the mucus barrier that colitis destroys.

,

Subject of Research: Commensal Lachnospiraceae bacterium mitigates colitis-induced mucin fucosylation deficits through ILC3/IL-22 axis

Article Title: Commensal Lachnospiraceae bacterium mitigates colitis-induced mucin fucosylation deficits through ILC3/IL-22 axis

Article References: Li, L., Jiang, J., Huang, Y., Yang, S., Wei, J., Dong, W., Zhong, W., Wang, B., Su, X., Cao, H., & Liu, T. (2026). Commensal Lachnospiraceae bacterium mitigates colitis-induced mucin fucosylation deficits through ILC3/IL-22 axis. Genome Biology. https://doi.org/10.1186/s13059-026-04304-7

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04304-7

Keywords: Commensal, Lachnospiraceae, bacterium, mitigates, colitis-induced, mucin, fucosylation, deficits, ILC3, IL-22, axis, scientific research

The patient’s ordeal began in April 2026, when she was referred to her general practitioner with back pain radiating down her right leg. She received a five-day course of intramuscular corticosteroids, a muscle relaxant, and the anti-inflammatory drug diclofenac. The treatment brought only slight relief, but something far more alarming appeared: extensive hematomas bloomed at every injection site. That unexpected bleeding prompted laboratory tests, and the results were grim. Her hemoglobin had crashed to 66 grams per liter, a level consistent with severe anemia, and her platelet count had fallen to 107 billion per liter, well below the normal range. Elevated bilirubin hinted that red blood cells were being destroyed somewhere inside her circulation.

By the time she was admitted to the hematology clinic the following day, the picture had crystallized into something hematologists recognize instantly and fear deeply. Her blood smear showed schistocytes, fragmented red cells sheared apart as they squeezed through obstructed microvessels, making up a staggering 30 percent of her red cell population. Lactate dehydrogenase, a marker of cell destruction, was massively elevated at 1744 units per liter. Haptoglobin, a protein that mops up free hemoglobin, was undetectable. The Coombs test was negative, ruling out autoimmune destruction. Her platelet count kept falling, dropping to 29 billion per liter within days. Everything pointed to thrombotic microangiopathy, a family of disorders in which tiny blood clots shred red cells and consume platelets throughout the body.

The leading suspect was thrombotic thrombocytopenic purpura, or TTP, a fulminant condition caused by severe deficiency of the ADAMTS13 enzyme, which normally cleaves ultra-large von Willebrand factor in the blood. The patient’s PLASMIC score, a validated prediction tool, came back at 6, indicating a high probability of TTP. Following standard practice, clinicians did not wait for the enzyme result. Plasma exchange, the lifesaving mainstay of TTP treatment, was started immediately alongside corticosteroids. But the therapy failed. Her clinical condition and laboratory parameters showed no improvement, and when ADAMTS13 activity finally returned it was completely normal at 108.4 percent. TTP was excluded, the plasma exchange was stopped, and the diagnostic search pivoted toward a far more sinister possibility: a secondary microangiopathic hemolytic anemia driven by an underlying malignancy.

Cancer-related microangiopathic hemolytic anemia, abbreviated CR-MAHA, was first described by Brain and colleagues in 1970, who distinguished it from other thrombotic microangiopathies by its association with disseminated cancer, particularly mucin-producing tumors of the stomach, breast, and lung. The proposed mechanism was grimly elegant: tumor emboli lodging in the microvasculature and in-situ thrombosis mechanically fragmenting erythrocytes as they traverse the damaged vessels. The syndrome remains rare, documented mainly in individual case reports and small series, but the largest systematic review, encompassing 168 cases, found that adenocarcinomas dominate the list of culprits. Gastric carcinoma led at 26.2 percent, followed by breast, prostate, and lung cancers. More than 90 percent of patients had metastatic disease, and bone marrow infiltration was documented in over 80 percent of assessed cases.

The clues in this patient’s blood work soon multiplied. Tumor markers came back dramatically elevated: carcinoembryonic antigen at 101.7 micrograms per liter and carbohydrate antigen 72-4 exceeding 500 units per milliliter, roughly seventy times the upper reference limit. A re-review of her spinal MRI revealed multiple metastatic deposits throughout every visualized vertebra and her pelvic bones. Computed tomography of the chest, abdomen, and pelvis showed bilateral adrenal enlargement and abdominal lymphadenopathy with nodes up to 25 millimeters across. Gastric biopsies, taken through an endoscope that revealed macroscopically normal mucosa, showed only chronic gastritis, a deceptive finding given what lay beneath. The decisive evidence came from the bone marrow itself.

Bone marrow aspiration revealed clusters of metastatic cells, several times the size of a neutrophil, with eccentric nuclei occupying about three-quarters of the cell volume and abundant pale cytoplasm. The trephine biopsy showed near-complete replacement of normal hematopoietic tissue by metastatic adenocarcinoma composed of discohesive cells stuffed with intracytoplasmic mucin that pushed their nuclei to the periphery, producing the classic signet-ring appearance that gives this tumor its name. Immunohistochemistry sealed the diagnosis: the cells expressed CK7, CK20, CDX2, MUC1, MUC2, and MUC5, while GATA3 was negative. This immunophenotypic profile, combined with the soaring CA 72-4 level, pointed squarely to a gastrointestinal primary, most consistent with metastatic gastric signet-ring-cell adenocarcinoma. Colonoscopy could not be performed because of her poor condition. Referred to oncology, she could not receive cancer-directed treatment because of persistent severe thrombocytopenia. She died six days later.

Why does this particular cancer trigger such catastrophic blood destruction? The answer appears to lie in mucins, the sugar-decorated glycoproteins that signet-ring-cell carcinomas manufacture in abundance. Mucins can bind P-selectin on platelets and L-selectin on leukocytes, promoting the formation of platelet-leukocyte aggregates that seed microvascular thrombosis, sometimes without conventional thrombin generation. The same interaction underlies Trousseau syndrome, the migratory thrombophlebitis that has haunted cancer patients since the nineteenth century. Many of these tumors also express tissue factor, releasing procoagulant microvesicles that generate thrombin and deposit fibrin diffusely, blurring the line with disseminated intravascular coagulation. Loss of E-cadherin, a hallmark of diffuse-type gastric cancer, facilitates the early peritoneal and bone marrow dissemination characteristic of signet-ring-cell tumors, whose thin-walled, highly permeable sinusoids may create microenvironments especially vulnerable to erythrocyte fragmentation.

The case carries a practical message for clinicians everywhere: when microangiopathic hemolysis fails to respond to plasma exchange and ADAMTS13 activity is normal, the workup must not stop. Tumor-marker assessment, cross-sectional imaging, and, crucially, bone marrow examination should follow promptly, particularly when unexplained cytopenias or a leucoerythroblastic blood picture suggest marrow involvement. In this patient, bone marrow aspiration provided the first direct evidence of metastatic carcinoma and substantially accelerated the diagnosis before histopathological confirmation. Distinguishing CR-MAHA from TTP and DIC matters enormously, because fibrinogen, coagulation times, D-dimer levels, and the response to plasma exchange all differ across these entities, and the treatments are fundamentally incompatible. Plasma exchange, a cornerstone of TTP therapy, offers no sustained benefit in CR-MAHA when the underlying malignancy remains untreated.

The story is ultimately a tragic one, but it is also a scientific one. It demonstrates how a single blood smear, read carefully, can expose an entire hidden pathology, and how the peculiar biology of a mucin-producing tumor can announce itself through the destruction of red blood cells rather than through pain, weight loss, or any symptom a patient might recognize. For a woman with back pain and no prior medical history, the interval from first symptom to fatal diagnosis was measured in weeks. The clinicians who reported her case hope that by documenting the diagnostic pathway, the laboratory red flags, and the pitfalls of anchoring on TTP, they can help the next patient reach a diagnosis early enough for cancer-directed therapy to begin while there is still time for it to matter.

Subject of Research: Cancer-related microangiopathic hemolytic anemia revealing occult metastatic gastrointestinal signet-ring-cell carcinoma

Article Title: Cancer‐Related Microangiopathic Haemolytic Anemia Revealing Occult Metastatic Gastrointestinal Signet‐Ring Cell Carcinoma: A Clinicopathological Case Report and Practical Differential Diagnostic Approach

Article References: Jovanovic, D., Sretenovic, S., Jovanovic, D., Ilic, M., & Djurdjevic, P. (2026). Cancer‐Related Microangiopathic Haemolytic Anemia Revealing Occult Metastatic Gastrointestinal Signet‐Ring Cell Carcinoma: A Clinicopathological Case Report and Practical Differential Diagnostic Approach. Clinical Case Reports, 14(10), Article e73675. https://doi.org/10.1002/ccr3.73675

Image Credits: AI Generated

DOI: 10.1002/ccr3.73675

Keywords: microangiopathic hemolytic anemia, signet-ring-cell carcinoma, gastric cancer, thrombotic thrombocytopenic purpura, ADAMTS13, bone marrow metastasis, mucin, tumor markers, disseminated intravascular coagulation, plasma exchange, schistocytes, case report